Studieninformationen
Kurztitel:
Cabocare
Beschreibung:
Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
Studiendesign:
Anwendungsbeobachtung, Beobachtend, Resultatsorientiert, Epidemiologisch, Multizentrisch, International
Therapielinien:
Erstlinie
Alter:
>= 18 Jahre
Ein-/Ausschlusskriterien:
Inclusion Criteria: Males or females aged 18 years and older with capacity to consent. Subjects receiving cabozantinib as monotherapy or in combination with nivolumab as a first line treatment for advanced or metastatic renal cell carcinoma Subjects with the intention to be treated with cabozantinib tablets as monotherapy or in combination with nivolumab according to the current local Summary of Product Characteristics (SmPC); decision has to be taken before entry in the study. Signed written informed consent Exclusion Criteria: Participation in an interventional study at the same time and/or within 3 months before baseline. Previous participation in this study
NCT-Nummer:
Studienaktive Standorte
Rekrutierung läuft
Praxis Dr. Welslau
Herr Dr. Manfred Welslau
m.welslau@onkologie-ab.de